Biopharmaceutical News and Research

RSS

Intellect Neurosciences: Several significant stakeholders commit funds

Intellect Neurosciences, Inc., a biopharmaceutical company focused on development of disease-modifying therapeutic agents for Alzheimer's disease ("AD"), announced today that several of its significant shareholders (the "Interested Shareholders") have agreed in principle to provide interim funding to the Company and assist the Company in its efforts to restructure its balance sheet.

11 Feb 2010

Indiana's pharmaceutical research and manufacturing companies maintained steady growth in 2009

Indiana's contract pharmaceutical research and manufacturing companies continued to expand in 2009, despite challenges in the biopharmaceutical contract service sector due to the downturn in the economy, the prospect of healthcare reform and other market developments.

11 Feb 2010

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

PLAN C Agency, in collaboration with biopharmaceutical company Gilead Sciences, launched a Hepatitis B awareness campaign titled "B HERE" at three college campuses in the West Coast. The goal was to raise the much needed awareness regarding the rising epidemic of Hepatitis B among Asian Americans and educate the youth on the importance of getting tested.

11 Feb 2010

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

MDS Inc., a leading provider of products and services to the global life sciences markets, today announced that it has signed agreements to divest its remaining MDS Pharma Services Early Stage business, which provides Discovery through Phase IIa clinical trial services to biotechnology and pharmaceutical companies, for $45 million and certain minority equity interests.

10 Feb 2010

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Avrio Biopharmaceuticals, LLC, a wholly-owned subsidiary of Irvine Pharmaceutical Services, Inc., received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB), completing the organization's portfolio of product development services in support of its pharmaceutical, biopharmaceutical, and medical device clients.

10 Feb 2010

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 second quarter, ended December 31, 2009.

10 Feb 2010

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces the publication of an article, entitled “A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series," authored by Dr. Matthew C. Foote, Dr. Bryan H. Burmeister, Janine Thomas, and Dr. B. Mark Smithers, in the current issue of the peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010).

10 Feb 2010

Sartorius releases preliminary unaudited figures for fiscal 2009

Today Sartorius, a leading international process and laboratory technology provider, released its preliminary unaudited figures for fiscal 2009. In the reporting period, business in both Group divisions showed substantially divergent trajectories.

From Sartorius 10 Feb 2010

Thrombogenics announces publication of positive microplasmin Phase II trial results

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.

9 Feb 2010

Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinson’s disease biomarker

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research (MJFF). The grant is to fund a project entitled: “Development of an alpha6*-selective Neuronal Nicotinic Receptor (NNR) Imaging Agent as a Parkinson’s Disease Biomarker” and is the second awarded to Targacept by MJFF in the last six months.

9 Feb 2010

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.

9 Feb 2010

GeoVax Labs provides updates on HIV-1 vaccine trials

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today provided an update on its vaccine trials progress.

9 Feb 2010

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

Cancer Research UK's commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday).

9 Feb 2010

Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the Phase 3 clinical study named VISTA-16 (Vascular Inflammation Suppression to Treat Acute Coronary Syndrome - 16 Weeks) for its lead product candidate, A-002, an oral sPLA2 inhibitor, in combination with HMG-CoA reductase inhibitor, or statin, therapy for short-term (16-week) treatment of patients experiencing an acute coronary syndrome.

8 Feb 2010

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia in China.

8 Feb 2010

AMAG Pharmaceuticals releases safety update on Feraheme Injection

AMAG Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, today provided a safety update on Feraheme® (ferumoxytol) Injection for intravenous use.

6 Feb 2010

Biotechnology: The next medical revolution

A recent article in the Scandia Journal reported that biotechnology is helping to improve our knowledge of many devastating illnesses, and has armed patients and their doctors with exciting new diagnostics and treatments to battle disease.

5 Feb 2010

Centerphase Solutions and Mayo Clinic collaborate to speed up clinical trials for new medical treatments

Centerphase has entered into a collaboration with Mayo Clinic to speed the introduction of new medical treatments developed by the biopharmaceutical industry. The Company addressed the root causes historically plaguing the clinical trials process: the lack of a systematic, structured approach for evaluating and optimizing protocols and the tremendous burdens associated with trial start-up administration.

5 Feb 2010

Pharma IQ to organize 4th Improving Solubility conference at The Park Hyatt in Philadelphia

Organized by Pharma IQ, a division of IQPC, the 4th Improving Solubility conference will be held March 29-31, 2010 at The Park Hyatt in Philadelphia, PA. This forum brings together pharmaceutical researchers and scientists to uncover advances in enhancing solubility, amorphous forms, bioavailability & lipid-based formulation of drugs.

From IQPC Ltd 5 Feb 2010

ABC Laboratories expands offering to include comprehensive support for large molecule development

Recognizing an increased industry need for outsourced biopharmaceutical drug development services, Analytical Bio-Chemistry Laboratories (ABC) has expanded its offering to include comprehensive support for large molecule development.

5 Feb 2010

Biopharmaceutical News and Research

Intellect Neurosciences: Several significant stakeholders commit funds

Indiana's pharmaceutical research and manufacturing companies maintained steady growth in 2009

PLAN C Agency launches Hepatitis B awareness campaign in the West Coast

MDS to divest remaining MDS Pharma Services Early Stage business for $45M

Avrio Biopharmaceuticals receives Cal FDB approval to manufacture and ship pharmaceutical products

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Sartorius releases preliminary unaudited figures for fiscal 2009

Thrombogenics announces publication of positive microplasmin Phase II trial results

Targacept receives grant for developing alpha6*-selective NNR Imaging Agent as Parkinson’s disease biomarker

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

GeoVax Labs provides updates on HIV-1 vaccine trials

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

AMAG Pharmaceuticals releases safety update on Feraheme Injection

Biotechnology: The next medical revolution

Centerphase Solutions and Mayo Clinic collaborate to speed up clinical trials for new medical treatments

Pharma IQ to organize 4th Improving Solubility conference at The Park Hyatt in Philadelphia

ABC Laboratories expands offering to include comprehensive support for large molecule development

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News